TITLE

Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome

AUTHOR(S)
Sanyal, Arun J.; Contos, Melissa J.; Sterling, Richard K.; Luketic, Velimir A.; Shiffman, Mitchell L.; Stravitz, R. Todd; Mills, A. Scott
PUB. DATE
September 2003
SOURCE
American Journal of Gastroenterology;Sep2003, Vol. 98 Issue 9, p2064
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: ObjectivesThe objectives of this study were to determine the following: 1) whether chronic hepatitis C virus (HCV) infection was specifically associated with nonalcoholic fatty liver disease (NAFLD); 2) the factors associated with NAFLD in patients with HCV; and 3) the clinical and histological spectrum of NAFLD occurring together with HCV.: MethodsA retrospective analysis of 3826 biopsies was performed to compare the prevalence of NAFLD in those with HCV versus that in other liver diseases, e.g., hepatitis B, primary biliary cirrhosis, and α1-antitrypsin deficiency. Patients with HCV and NAFLD were also compared with an age- and gender-matched control group with HCV and <5% hepatic steatosis.: ResultsThe prevalence of NAFLD in patients with HCV was similar to that in hepatitis B, primary biliary cirrhosis, or α1-antitrypsin deficiency. The risk of having NAFLD in patients with HCV correlated with body weight (r = 0.7, p < 0.02). Compared with a control group with HCV alone (n = 75), patients with HCV and NAFLD (n = 69) were likely to be heavier (mean BMI 27 vs 30, p < 0.003), diabetic (eight vs 21, p < 0.005), hypertensive (14 vs 25, p < 0.05), and hypertriglyceridemic (15 vs 33, p < 0.05). The HCV viral load, genotype distribution, liver enzymes, liver functions, and ferritin levels were comparable across the study groups. Those with HCV and NAFLD were more likely to have advanced fibrosis (bridging fibrosis or cirrhosis) (26% vs 53%, p < 0.03). Weight, diabetes, and cytological ballooning were independent predictors of advanced fibrosis in those with HCV and NAFLD.: ConclusionsThe presence of NAFLD in patients with HCV is strongly associated with features of the metabolic syndrome and is a risk factor for advanced fibrosis. Advanced fibrosis in such patients is related to weight, presence of diabetes, and presence and degree of cytological ballooning.
ACCESSION #
10807811

 

Related Articles

  • Human Immunodeficiency Virus and Hepatitis C Virus: Which Is the Cart, and Which Is the Horse? Girón-González, José A.; Martinez-Sierra, Carmen; Arizcorreta, Ana; Díaz, Fernando // Clinical Infectious Diseases;9/1/2003, Vol. 37 Issue 5, p740 

    Informs about the evolution of liver disease in HIV-infected patients is influenced by the baseline CD4 cell count and the hepatitis C virus load. Relationship between the increase in CD4 cell count and the severity of the liver disease; Information about a study on the topic.

  • Within-host and between-host evolutionary rates across the HIV-1 genome. Alizon, Samuel; Fraser, Christophe // Retrovirology;2013, Vol. 10 Issue 1, p1 

    Background: HIV evolves rapidly at the epidemiological level but also at the within-host level. The virus' within-host evolutionary rates have been argued to be much higher than its between-host evolutionary rates. However, this conclusion relies on analyses of a short portion of the virus...

  • HCV and HIV binding lectin, DC-SIGNR, is expressed at all stages of HCV induced liver disease. Cole G; Coleman N; Soilleux E // Journal of Clinical Pathology;Jan2004, Vol. 57 Issue 1, p79 

    The process by which hepatitis C virus (HCV) enters cells and the reason for its hepatotropism remain obscure. Recently, the human immunodeficiency virus (HIV) binding lectins, DC-SIGN and DC-SIGNR, were shown to bind HCV. This article reports the expression of DC-SIGN and DC-SIGNR in HCV...

  • Practical considerations for sensitivity analysis after multiple imputation applied to epidemiological studies with incomplete data. H‚raud-Bousquet, Vanina; Larsen, Christine; Carpenter, James; Desenclos, Jean-Claude; Le Strat, Yann // BMC Medical Research Methodology;2012, Vol. 12 Issue 1, p73 

    Background: Multiple Imputation as usually implemented assumes that data are Missing At Random (MAR), meaning that the underlying missing data mechanism, given the observed data, is independent of the unobserved data. To explore the sensitivity of the inferences to departures from the MAR...

  • HIV Infection and Antiretroviral Therapy: Effect on Hepatitis C Virus Quasispecies Variability. Shuhart, Margaret C.; Sullivan, Daniel G.; Bekele, Kirubeal; Harrington, Robert D.; Kitahata, Mari M.; Mathisen, Terri L.; Thomassen, Lisa V.; Emerson, Scott S.; Gretch, David R. // Journal of Infectious Diseases;5/1/2006, Vol. 193 Issue 9, p1211 

    Background. Hepatitis C virus (HCV) quasispecies variability has been associated with liver disease progression. The effects of human immunodeficiency virus (HIV) coinfection and highly active antiretroviral therapy (HAART) on HCV quasispecies variability have not been firmly established....

  • Association of HCV with diabetes mellitus: an Egyptian case-control study.  // Virology Journal;2011, Vol. 8 Issue 1, p367 

    The article focuses on a case-control study, conducted to evaluate the prevalence of DM and other extrahepatic (EH) manifestations among patients with different hepatitis C virus (HCV) morbidity stages in Egypt. The study found out of 289 HCV cases, 40 were diabetic and the diabetic HCV group...

  • Outcomes among Patients with End-Stage Liver Disease Who Are Coinfected with HIV and Hepatitis C Virus. Neff, Guy W.; Shire, Norah J.; Rudich, Steven M. // Clinical Infectious Diseases;7/1/2005 Supplement, Vol. 41, pS50 

    In at-risk populations, shared routes of transmission lead to high rates of concordance between infection with human immunodeficiency virus (HIV) type 1 and hepatitis C virus (HCV). In the era of highly active anti-retroviral therapy (HAART), end-stage liver disease (ESLD) has emerged as a...

  • Delivering Therapy for Hepatitis C Virus Infection to Incarcerated HIV-Seropositive Patients. Mcgovern, Barbara; Fiore, Joseph; Wurcel, Alysse; Taglienti, Paul; Bradley, Meg; Galvin, Susan; Libone, George; Ramsey, Jean; Molinaro-Gudas, Valerie; Drewniak, Stephen; Amick, Carol; Andalkar, Anjali; Scheft, Harriet; Bica, Ioana // Clinical Infectious Diseases;7/1/2005 Supplement, Vol. 41, pS56 

    The increase in morbidity and mortality due to end-stage liver disease has fueled recent guidelines that recommend consideration of treatment for hepatitis C in human immunodeficiency virus (HIV)-infected patients. Unfortunately, studies indicate that few patients coinfected with HIV and...

  • Hepatopulmonary Syndrome in HIV--Hepatitis C Virus Coinfection: A Case Report and Review of the Literature. Torno, Mauro S.; Witt, Mallory D.; Sue, Darryl Y. // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, pe25 

    A wide array of diagnoses must be considered when a patient with advanced liver disease and human immunodeficiency virus (HIV) infection presents with hypoxemia. It is important to entertain the possibility of hepatopulmonary syndrome (HPS) in such patients, a diagnosis that must be confirmed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics